Rabbit Recombinant Monoclonal NAT1 antibody. Suitable for WB, ICC/IF, Flow Cyt (Intra) and reacts with Human samples. Cited in 8 publications.
pH: 7.2 - 7.4
Preservative: 0.05% Sodium azide
Constituents: 50% Tissue culture supernatant, 40% Glycerol (glycerin, glycerine), 9.85% Tris glycine, 0.1% BSA
IP | WB | IHC-P | ICC/IF | Flow Cyt (Intra) | |
---|---|---|---|---|---|
Human | Not recommended | Tested | Not recommended | Tested | Tested |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info 1/1000 - 1/10000 | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info 1/100 - 1/250 | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info 1/100 | Notes ab172730 - Rabbit monoclonal IgG, is suitable for use as an isotype control with this antibody. |
Select an associated product type
Participates in the detoxification of a plethora of hydrazine and arylamine drugs. Catalyzes the N- or O-acetylation of various arylamine and heterocyclic amine substrates and is able to bioactivate several known carcinogens.
AAC1, NAT1, Arylamine N-acetyltransferase 1, Arylamide acetylase 1, Monomorphic arylamine N-acetyltransferase, N-acetyltransferase type 1, MNAT, NAT-1
Rabbit Recombinant Monoclonal NAT1 antibody. Suitable for WB, ICC/IF, Flow Cyt (Intra) and reacts with Human samples. Cited in 8 publications.
pH: 7.2 - 7.4
Preservative: 0.05% Sodium azide
Constituents: 50% Tissue culture supernatant, 40% Glycerol (glycerin, glycerine), 9.85% Tris glycine, 0.1% BSA
Mouse, Rat: We have preliminary internal testing data to indicate this antibody may not react with these species. Please contact us for more information.
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
This product is a recombinant monoclonal antibody, which offers several advantages including:
For more information, read more on recombinant antibodies.
NAT1 also known as arylamine N-acetyltransferase 1 serves as an important enzyme in acetylation reactions. This enzyme with a molecular mass of approximately 33 kDa catalyzes the transfer of acetyl groups to arylamines and other substrates such as hydrazines. By doing so NAT1 influences xenobiotic metabolism. The enzyme is expressed in various tissues most notably in the liver intestine and lung which aligns with its role in detoxifying and metabolizing drugs and carcinogens.
NAT1 plays a significant role in detoxifying environmental toxins and carcinogens. The enzyme's activity contributes to the acetylation a phase II metabolic reaction which often converts lipophilic substrates into more hydrophilic products for excretion. NAT1 stands independently and does not form part of a larger complex. It shares functional similarities with other N-acetyltransferases but its substrate specificity can differ which influences its distinct biological role.
NAT1 is intricately involved in metabolic and detoxification pathways. It participates in the biotransformation of various drugs and environmental carcinogens making it important for xenobiotic metabolism. NAT1 often interacts with cytochrome P450 enzymes during these processes which also contribute to the initial phase I oxidation reactions. The interplay between NAT1 and these detoxification pathways highlights the enzyme's contribution to reducing potential toxicities.
NAT1 has associations with both cancer and hypersensitivity to certain drugs. Variations in NAT1 activity due to genetic polymorphisms can influence individual susceptibility to cancers particularly bladder cancer linked to arylamine exposure. Additionally its interaction with cytochrome P450 enzymes may also impact drug metabolism potentially leading to adverse drug reactions. Understanding NAT1 and its interactions help assess risks related to these diseases.
We have tested this species and application combination and it works. It is covered by our product promise.
We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.
This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.
We do not recommend this combination. It is not covered by our product promise.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
All lanes: Western blot - Anti-NAT1 antibody [EPR3221(2)] (ab109114) at 1/1000 dilution
Lane 1: U937 cell lysate at 10 µg
Lane 2: Fetal liver cell lysate at 10 µg
Lane 3: LnCaP cell lysate at 10 µg
Lane 4: Human bladder cell lysate at 10 µg
Lane 5: HT-1376 cell lysate at 10 µg
Predicted band size: 34 kDa
Flow Cytometry analysis of LNCaP (Human prostate carcinoma epithelial cell) cells labeling NAT1 with purified ab109114 at 1/100 dilution (10 μg/mL) (Red). Cells were fixed with 4% Paraformaldehyde and permeabilised with 90% Methanol. A Goat anti rabbit IgG (Alexa Fluor® 488, Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488) ab150077) secondary antibody was used at 1/2000. Isotype control - Rabbit monoclonal IgG (Black). Unlabeled control - Cell without incubation with primary antibody and secondary antibody (Blue).
Immunofluorescent staining of LN-CAP cells using anti-NAT1 at 1/100 (ab109114).
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com